126 related articles for article (PubMed ID: 26004876)
1. Anaphylactic reaction and cardiac arrest due to gadobenate dimeglumine.
Virtos M; Ruiz S; Mokrane FZ; Rousseau H; Georges B; Fourcade O; Conil JM
Anaesth Crit Care Pain Med; 2015 Aug; 34(4):247-8. PubMed ID: 26004876
[No Abstract] [Full Text] [Related]
2. Severe adverse drug reaction to gadobenate dimeglumine.
Singer BD; Woodrick RS; Pedicano JB
ScientificWorldJournal; 2009 May; 9():363-5. PubMed ID: 19468658
[TBL] [Abstract][Full Text] [Related]
3. A case of gadobenate dimeglumine-induced anaphylactic shock: a case report.
Huang J; Liu Z; Jiang C; Xu L; Zheng W
Ann Palliat Med; 2021 Jun; 10(6):7126-7131. PubMed ID: 34154335
[TBL] [Abstract][Full Text] [Related]
4. Small bowel angioedema due to intravenous administration of gadobenate dimeglumine.
Maarek R; Sellier N; Seror O; Sutter O
Diagn Interv Imaging; 2019; 100(7-8):459-460. PubMed ID: 30935862
[No Abstract] [Full Text] [Related]
5. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
Campos A; Aznar L; Alamar R; Castelló JV
Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
[No Abstract] [Full Text] [Related]
6. Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment.
Hasdenteufel F; Luyasu S; Renaudin JM; Paquay JL; Carbutti G; Beaudouin E; Moneret-Vautrin DA; Kanny G
J Allergy Clin Immunol; 2008 Feb; 121(2):527-8. PubMed ID: 17919712
[No Abstract] [Full Text] [Related]
7. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
8. Fatal reaction to gadopentetate dimeglumine.
Jordan RM; Mintz RD
AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905
[No Abstract] [Full Text] [Related]
9. Interim results of phase II clinical testing of gadobenate dimeglumine.
Rosati G; Pirovano G; Spinazzi A
Invest Radiol; 1994 Jun; 29 Suppl 2():S183-5. PubMed ID: 7928224
[No Abstract] [Full Text] [Related]
10. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
11. Cardiac electrophysiologic monitoring after injection of gadobenate dimeglumine versus placebo in healthy volunteers and patients with cardiovascular disease.
Pirovano G; Goodman DB; Halemane U; Venetianer C; Kirchin MA; Spinazzi A
Radiology; 2004 Nov; 233(2):555-65. PubMed ID: 15375224
[TBL] [Abstract][Full Text] [Related]
12. Anaphylactic shock induced by intravenous gadopentetate dimeglumine.
Tardy B; Guy C; Barral G; Page Y; Ollagnier M; Bertrand JC
Lancet; 1992 Feb; 339(8791):494. PubMed ID: 1346846
[No Abstract] [Full Text] [Related]
13. Gadobenate dimeglumine (Gd-BOPTA). An overview.
Kirchin MA; Pirovano GP; Spinazzi A
Invest Radiol; 1998 Nov; 33(11):798-809. PubMed ID: 9818314
[No Abstract] [Full Text] [Related]
14. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Bryant BJ; Im K; Broome DR
Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
[TBL] [Abstract][Full Text] [Related]
15. Anaphylactic shock induced by gadoterate meglumine (DOTAREM).
Beaudouin E; Kanny G; Blanloeil Y; Guilloux L; Renaudin JM; Moneret-Vautrin DA
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):382-5. PubMed ID: 14768523
[TBL] [Abstract][Full Text] [Related]
16. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
17. Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease.
Martin DR; Kalb B; Mittal A; Salman K; Vedantham S; Mittal PK
Radiology; 2018 Jan; 286(1):113-119. PubMed ID: 28731375
[TBL] [Abstract][Full Text] [Related]
18. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
Bleicher AG; Kanal E
AJR Am J Roentgenol; 2008 Dec; 191(6):W307-11. PubMed ID: 19020220
[TBL] [Abstract][Full Text] [Related]
19. Anaphylaxis to gadobenate dimeglumine (Multihance): a case report.
Kalogeromitros DC; Makris MP; Aggelides XS; Spanoudaki N; Gregoriou SG; Avgerinou G; Rigopoulos DG
Int Arch Allergy Immunol; 2007; 144(2):150-4. PubMed ID: 17536224
[TBL] [Abstract][Full Text] [Related]
20. Gadobenate dimeglumine in MRI of acute myocardial infarction: results of a phase III study comparing dynamic and delayed contrast enhanced magnetic resonance imaging with EKG, (201)Tl SPECT, and echocardiography.
Cherryman GR; Pirovano G; Kirchin MA
Invest Radiol; 2002 Mar; 37(3):135-45. PubMed ID: 11882793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
